| Literature DB >> 35312321 |
Sungbo Hwang1, Seung-Hwa Baek1,2, Daeui Park1,2.
Abstract
In the past 2 years, since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), multiple SARS-CoV-2 variants have emerged. Whenever a new variant emerges, considerable time is required to analyze the binding affinity of the viral surface proteins to human angiotensin-converting enzyme 2 (hACE2) and monoclonal antibodies. To efficiently predict the binding affinities associated with hACE2 and monoclonal antibodies in a short time, herein, we propose a method applying statistical analysis to simulations performed using molecular and quantum mechanics. This method efficiently predicted the trend of binding affinity for the binding of the spike protein of each variant of SARS-CoV-2 to hACE2 and individually to eight commercial monoclonal antibodies. Additionally, this method accurately predicted interaction energy changes in the crystal structure for 10 of 13 mutated residues in the Omicron variant, showing a significant change in the interaction energy of hACE2. S375F was found to be a mutation that majorly changed the binding affinity of the spike protein to hACE2 and the eight monoclonal antibodies. Our proposed analysis method enables the prediction of the binding affinity of new variants to hACE2 or to monoclonal antibodies in a shorter time compared to that utilized by the experimental method.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35312321 PMCID: PMC8982492 DOI: 10.1021/acs.jcim.2c00100
Source DB: PubMed Journal: J Chem Inf Model ISSN: 1549-9596 Impact factor: 4.956
Figure 1Distribution of pair interaction energy (a) between hACE2 and four types of spike proteins and (b) between each residue of hACE2 and the spike protein of the wild type and the two Omicron variants. Asterisks indicate statistically significant variation (Student’s t-test, **P-value < 0.01, ***P-value < 0.001).
Median Interaction Energy of Residues in the Receptor Binding Domain Interacting with hACE2 Obtained Using Protein–Protein Docking Simulationsa
| Omicron
(Q493K) | Omicron
(Q493R) | ||||
|---|---|---|---|---|---|
| residue | energy with wild type (kcal/mol) | energy | energy | ||
| G339D | 12.7 | 38.1 | 5.4 × 10–32 | 40.0 | 4.3 × 10–31 |
| S371L | –12.5 | 2.6 × 10–1 | 2.6 × 10–3 | ||
| S373P | –13.4 | –2.2 | 6.3 × 10–28 | –1.9 | 5.0 × 10–29 |
| 5.1 × 10–6 | 6.8 × 10–4 | ||||
| K417N | –69.6 | 5.6 | 6.8 × 10–22 | 6.7 | 1.9 × 10–22 |
| 1.6 × 10–31 | 1.5 × 10–29 | ||||
| G446S | –2.0 | 10.7 | 1.9 × 10–15 | 12.4 | 1.5 × 10–12 |
| S477N | 13.8 | 16.6 | 1.1 × 10–3 | 16.3 | 1.5 × 10–3 |
| 1.1 × 10–18 | 2.8 × 10–22 | ||||
| 2.3 × 10–28 | 5.5 × 10–27 | ||||
| 3.4 × 10–25 | 5.8 × 10–14 | ||||
| G496S | –5.9 | 4.9 | 9.0 × 10–3 | –4.0 | 2.8 × 10–1 |
| 4.8 × 10–21 | 5.8 × 10–19 | ||||
| N501Y | –9.1 | –0.4 | 2.1 × 10–4 | –0.7 | 2.2 × 10–6 |
| Y505H | 16.4 | 13.6 | 5.9 × 10–1 | 0.3 | 1.5 × 10–1 |
Underlined residues and values indicate significantly stronger interactions in the Omicron variants than those in the wild type for which the P-value was less than 5.0 × 10–2 and the median interaction energy for the Omicron variant was lower than that for the wild type.
The Omicron variant containing Q493K showed no significantly stronger interaction, but the Omicron variant containing Q493R showed a significantly stronger interaction than that observed in the wild type.
Pair Interaction Energy of Residues of hACE2 and Residues of the Receptor Binding Domain in Crystal Structuresa
| pair
interaction energy (kcal/mol) with
hACE2 | ||
|---|---|---|
| residue | wild type | Omicron (Q493R) |
| G339D | 15.9 | 36.0 |
| S371L | –21.9 | –12.0 |
| S373P | –11.2 | 4.9 |
| K417N | –135.8 | 7.9 |
| G446S | –5.6 | 18.7 |
| Y505H | 4.0 | 6.8 |
Underlined residues and values represent stronger interactions in the Omicron variant than those in the wild type.
Figure 2Distribution of pair interaction energy (a) between hACE2 and three types of spike proteins and (b) between each residue of hACE2 and the spike protein of the wild type and Omicron variant. Asterisks indicate statistically significant variation (Student’s t-test, ***P-value < 0.001).
Median Interaction Energy of Residues in the Receptor Binding Domain Interacting with hACE2 Generated Using Molecular Dynamicsab
| median
interaction energy (kcal/mol) with
hACE2 | |||
|---|---|---|---|
| residue | wild type | Omicron (Q493R) | |
| G339D | 9.7 | 35.5 | 3.3 × 10–29 |
| S373P | –9.6 | 1.5 | 9.6 × 10–21 |
| K417N | –67.7 | 12.6 | 9.6 × 10–29 |
| G446S | –0.6 | 7.0 | 2.8 × 10–15 |
| S477N | 3.9 | 6.7 | 4.9 × 10–2 |
| G496S | –4.2 | –2.4 | 1.7 × 10–1 |
| N501Y | –31.7 | –23.9 | 9.3 × 10–4 |
| Y505H | –4.6 | –2.1 | 3.1 × 10–1 |
Underlined residues and values indicate significantly stronger interactions in the Omicron variant than those in the wild type for which the P-value was less than 5.0 × 10–2, and the median interaction energy of the Omicron variant was lower than that of the wild type.
Bold residues and values represent residues having significantly stronger interactions in protein–protein docking simulations for the Omicron variant than those of the wild type.
Figure 3Mutation points of the spike protein of the Omicron variant depicted in the spike protein of the wild type. Cyan-colored residues represent residues in the Omicron variant with weaker interactions than those in the wild type. Orange-colored residues represent residues in the Omicron variant with stronger interactions than those in the wild type.
Median Pair Interaction Energy between the Receptor Binding Domain and Eight Different Monoclonal Antibodiesa
| median
total interaction energy (kcal/mol) | ||||
|---|---|---|---|---|
| monoclonal antibody | wild type | Delta | Omicron (Q493K) | Omicron (Q493R) |
| regdanvimab | 909.6 | 1078.2 | ||
| (1.2 × 10–4) | ||||
| ( | ||||
| bamlavimab | 1202.1 | 1371.2 | ||
| (1.3 × 10–2) | ( | |||
| ( | ( | |||
| etesivimab | 895.4 | 1052.2 | 925.2 | 907.8 |
| (4.2 × 10–3) | (4.9 × 10–1) | (9.5 × 10–1) | ||
| (4. | (1.1 × 10–2) | |||
| casirivimab | 1002.6 | 990.0 | 976.5 | 1149.2 |
| (8.0 × 10–1) | (8.2 × 10–1) | (1.9 × 10–1) | ||
| (8.7 × 10–1) | (1.0 × 10–1) | |||
| imdevimab | 967.4 | 910.3 | ||
| (9.7 × 10–1) | ( | |||
| ( | ( | |||
| cilgavimab | 744.1 | 734.8 | 711.8 | 669.3 |
| (8.2 × 10–1) | (9.0 × 10–1) | (3.1 × 10–1) | ||
| (9.3 × 10–1) | (4.1 | |||
| tixagevimab | 990.4 | 958.9 | 1118.2 | |
| (9.1 × 10–1) | (3.7 × 10–2) | ( | ||
| (5.3 × 10–2) | ( | |||
| sotrovimab | 1006.8 | 873.7 | 1004.5 | 949.7 |
| (4.1 × 10–2) | (8.2 × 10–2) | (1.1 × 10–1) | ||
| (3.4 × 10–2) | (6.3 × 10–1) | |||
Underlined monoclonal antibodies are monoclonal antibodies for which the binding affinity with the Omicron variant was significantly weaker than that with the wild type and the Delta variant.
Values represent the P-value for the median total interaction energy between the wild type and the Delta variant.
Values represent the P-value for the median total interaction energy between the wild type and the Omicron variant.
Values represent the P-value for the median total interaction energy between the Delta and Omicron variants.
Residues in the Spike Protein Having Lower Pair Interaction Energy Compared to the Wild Type and the Omicron Varianta
| monoclonal antibody | residues |
|---|---|
| regdanvimab | S375F, N440K, T478K, E484A, Q493K, Q498R, Y505H |
| bamlavimab | S375F, N440K, T478K, E484A, Q493K, Q498R, Y505H |
| etesivimab | S375F, N440K, T478K, Q493K, Q498R |
| casirivimab | G339D, S375F, S477N, Q498R |
| imdevimab | G339D, S375F, N501Y, Y505H |
| cilgavimab | G339D, S371L, S373P, K417N, S477N, N501Y |
| tixagevimab | G339D, S375F, Y505H |
| sotrovimab | K417N, N440K |
Underlined residues are the residues in which the pair interaction energy for the Omicron variant was weaker than that of the wild type for the highest number of monoclonal antibodies.
Figure 4Flowchart showing (a) protein–protein docking simulation using the receptor binding domain of the spike protein, hACE2, and eight monoclonal antibodies and (b) molecular dynamic simulation using the predicted receptor binding domain structure superimposed on the crystal structure of the wild-type receptor binding domain.